#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	14208	16S	1529	1529	99.93	16S.l15.c4.ctg.1	2204	639.3	0	.	n	.	0	C207T	SNP	207	207	C	437	437	T	786	T,C	398,340	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	14208	16S	1529	1529	99.93	16S.l15.c4.ctg.1	2204	639.3	1	SNP	n	C1184T	0	.	.	1184	1184	C	1414	1414	C	824	C	772	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	25482	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3741	679.8	0	.	n	.	0	T695C	SNP	695	695	T	1070	1070	C	774	C	730	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	25482	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3741	679.8	0	.	n	.	0	T1971C	SNP	1971	1971	T	2346	2346	C	805	C	756	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	25482	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3741	679.8	1	SNP	n	A2045G	0	.	.	2045	2045	A	2420	2420	A	776	A	737	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	25482	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3741	679.8	1	SNP	n	C2597T	0	.	.	2597	2597	C	2972	2972	C	796	C	743	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	25482	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3741	679.8	0	HET	.	.	.	A1638G	.	1638	1638	A	2013	2013	A	833	A,G	488,309	.	.
folP.WHO_O_01412c	folP.WHO_O_01412c	1	1	27	1924	folP	855	855	100.0	folP.l15.c4.ctg.1	1565	122.3	1	SNP	p	R229S	1	.	.	685	687	AGC	1080	1082	AGC	165;165;164	A;G;C	158;159;155	folP.WHO_O_01412c:1:1:R229S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	5260	gyrA	2751	2751	99.85	gyrA.l6.c30.ctg.1	3540	148.3	1	SNP	p	S91F	1	.	.	271	273	TTC	672	674	TTC	185;187;187	T;T;C	176;176;176	gyrA.WHO_M_01098:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	5260	gyrA	2751	2751	99.85	gyrA.l6.c30.ctg.1	3540	148.3	1	SNP	p	D95G	1	.	.	283	285	GGC	684	686	GGC	184;185;187	G;G;C	177;177;175	gyrA.WHO_M_01098:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	5260	gyrA	2751	2751	99.85	gyrA.l6.c30.ctg.1	3540	148.3	1	SNP	p	G95N	0	.	.	283	285	GGC	684	686	GGC	184;185;187	G;G;C	177;177;175	gyrA.WHO_M_01098:1:1:G95N:gyrA.95N:Resistance to fluoroquinolones	.
mtrR.WHO_G_01393	mtrR.WHO_G_01393	1	1	27	1566	mtrR	633	633	100.0	mtrR.l15.c30.ctg.1	1330	117.4	1	SNP	p	G45D	0	.	.	133	135	GGC	513	515	GGC	196;198;202	G;G;C,A	185;186;187,1	mtrR.WHO_G_01393:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	762	mtrR_promoter	250	250	99.6	mtrR_promoter.l15.c30.ctg.1	1194	63.5	0	.	n	.	0	A197.	DEL	197	197	A	666	666	A	173	A	165	.	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	5294	parC	2304	2304	100.0	parC.l15.c30.ctg.1	2844	184.8	1	SNP	p	D86N	0	.	.	256	258	GAC	521	523	GAC	222;221;223	G;A;C	214;210;212	parC.WHO_Y_00247c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	5294	parC	2304	2304	100.0	parC.l15.c30.ctg.1	2844	184.8	1	SNP	p	R87I	0	.	.	259	261	CGT	524	526	CGT	224;223;222	C;G;T	211;212;210	parC.WHO_Y_00247c:1:1:R87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	5294	parC	2304	2304	100.0	parC.l15.c30.ctg.1	2844	184.8	1	SNP	p	R87W	0	.	.	259	261	CGT	524	526	CGT	224;223;222	C;G;T	211;212;210	parC.WHO_Y_00247c:1:1:R87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	5294	parC	2304	2304	100.0	parC.l15.c30.ctg.1	2844	184.8	1	SNP	p	S87R	1	.	.	259	261	CGT	524	526	CGT	224;223;222	C;G;T	211;212;210	parC.WHO_Y_00247c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	5294	parC	2304	2304	100.0	parC.l15.c30.ctg.1	2844	184.8	1	SNP	p	S88P	0	.	.	262	264	TCC	527	529	TCC	221;222;222	T;C;C	210;212;212	parC.WHO_Y_00247c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	4100	parE	1986	1986	100.0	parE.l15.c4.ctg.1	2652	154.2	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1504	1506	GGC	226;224;224	G;G;C	213;212;214	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.34.001	penA.34.001	1	1	27	3798	penA	1746	1746	100.0	penA.l15.c30.ctg.1	2393	157.6	1	SNP	p	A311V	0	.	.	931	933	GCC	1179	1181	GCC	211;212;213	G;C,T;C	196;198,1;201	penA.34.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	3798	penA	1746	1746	100.0	penA.l15.c30.ctg.1	2393	157.6	1	SNP	p	I312M	1	.	.	934	936	ATG	1182	1184	ATG	216;216;216	A;T;G	202;201;201	penA.34.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	3798	penA	1746	1746	100.0	penA.l15.c30.ctg.1	2393	157.6	1	SNP	p	V316T	1	.	.	946	948	ACC	1194	1196	ACC	235;235;236	A;C;C	217;217;219	penA.34.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	3798	penA	1746	1746	100.0	penA.l15.c30.ctg.1	2393	157.6	1	SNP	p	T316P	0	.	.	946	948	ACC	1194	1196	ACC	235;235;236	A;C;C	217;217;219	penA.34.001:1:1:T316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	3798	penA	1746	1746	100.0	penA.l15.c30.ctg.1	2393	157.6	1	SNP	p	T483S	0	.	.	1447	1449	ACC	1695	1697	ACC	196;198;200	A;C;C	181;185;188	penA.34.001:1:1:T483S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	3798	penA	1746	1746	100.0	penA.l15.c30.ctg.1	2393	157.6	1	SNP	p	A501V	0	.	.	1501	1503	GCG	1749	1751	GCG	195;195;198	G;C;G	187;188;190	penA.34.001:1:1:A501V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	3798	penA	1746	1746	100.0	penA.l15.c30.ctg.1	2393	157.6	1	SNP	p	A501P	0	.	.	1501	1503	GCG	1749	1751	GCG	195;195;198	G;C;G	187;188;190	penA.34.001:1:1:A501P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	3798	penA	1746	1746	100.0	penA.l15.c30.ctg.1	2393	157.6	1	SNP	p	G542S	0	.	.	1624	1626	GGT	1872	1874	GGT	137;137;140	G;G;T	124;125;127	penA.34.001:1:1:G542S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	3798	penA	1746	1746	100.0	penA.l15.c30.ctg.1	2393	157.6	1	SNP	p	G545S	1	.	.	1633	1635	AGC	1881	1883	AGC	133;128;129	A;G;C	118;116;118	penA.34.001:1:1:G545S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	3798	penA	1746	1746	100.0	penA.l15.c30.ctg.1	2393	157.6	1	SNP	p	P551S	0	.	.	1651	1653	CCG	1899	1901	CCG	115;116;117	C,G;C,G;G	91,6;89,2;90	penA.34.001:1:1:P551S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	5398	ponA	2397	2397	100.0	ponA.l15.c30.ctg.1	3070	175.1	1	SNP	p	L421P	1	.	.	1261	1263	CCG	1639	1641	CCG	205;208;205	C;C,T;G	186;194,1;186	ponA.WHO_G_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	2452	porA	1146	1146	99.91	porA.l15.c4.ctg.1	1732	140.3	0	.	p	.	0	M83fs	FSHIFT	247	247	A	569	569	C	187	C	172	.	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	539	2728	porB1b	1038	1038	99.9	porB1b.l15.c4.ctg.1	1794	151.6	0	.	p	.	0	I45V	NONSYN	133	135	ATT	458	460	GTT	223;224;223	G;T;T,G	213;212;213,1	.	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	539	2728	porB1b	1038	1038	99.9	porB1b.l15.c4.ctg.1	1794	151.6	1	SNP	p	G120K	1	.	.	358	360	AAG	683	685	AAG	223;221;222	A;A;G	214;209;210	porB1b.WHO_Y_02277c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	539	2728	porB1b	1038	1038	99.9	porB1b.l15.c4.ctg.1	1794	151.6	1	SNP	p	N121D	0	.	.	361	363	AAC	686	688	AAC	222;221;224	A;A;C	213;212;212	porB1b.WHO_Y_02277c:1:1:N121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	539	2728	porB1b	1038	1038	99.9	porB1b.l15.c4.ctg.1	1794	151.6	1	SNP	p	A121N	1	.	.	361	363	AAC	686	688	AAC	222;221;224	A;A;C	213;212;212	porB1b.WHO_Y_02277c:1:1:A121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	27	9786	rpoB	4179	4179	99.98	rpoB.l15.c17.ctg.1	4811	202.8	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	1080	rpsJ	312	312	100.0	rpsJ.l15.c17.ctg.1	1009	105.7	1	SNP	p	V57M	1	.	.	169	171	ATG	501	503	ATG	212;211;212	A;T;G	202;202;203	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
